Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy
Elsayed, Z., Elkady, M., Elmmonem Biomy, W., Ezz El Din, M., El Mahdy, M., Omran, T., Sabra, R. (2018). Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy. EKB Journal Management System, 72(10), 5466-5469. doi: 10.21608/ejhm.2018.11360
Zeinab Mohammed Abdel-Hafeez Elsayed; Mohammad Sabry Elkady; Waleed Abd Elmmonem Biomy; Mai Mohamed Ali Ezz El Din; Manal Mohamed El Mahdy; Tag Ibrahim Omran; Radwa Mohamed Sabra. "Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy". EKB Journal Management System, 72, 10, 2018, 5466-5469. doi: 10.21608/ejhm.2018.11360
Elsayed, Z., Elkady, M., Elmmonem Biomy, W., Ezz El Din, M., El Mahdy, M., Omran, T., Sabra, R. (2018). 'Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy', EKB Journal Management System, 72(10), pp. 5466-5469. doi: 10.21608/ejhm.2018.11360
Elsayed, Z., Elkady, M., Elmmonem Biomy, W., Ezz El Din, M., El Mahdy, M., Omran, T., Sabra, R. Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy. EKB Journal Management System, 2018; 72(10): 5466-5469. doi: 10.21608/ejhm.2018.11360

Predictive and Prognostic Impact of Tumor-Infiltrating Lymphocytes (CD8+) In Breast Cancer Treated With Neoadjuvant Chemotherapy

The Egyptian Journal of Hospital Medicine
Article 22, Volume 72, Issue 10, July 2018, Page 5466-5469  XML PDF (337.46 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2018.11360
View on SCiNiTO View on SCiNiTO
Authors
Zeinab Mohammed Abdel-Hafeez Elsayed1; Mohammad Sabry Elkady1; Waleed Abd Elmmonem Biomy1; Mai Mohamed Ali Ezz El Din1; Manal Mohamed El Mahdy2; Tag Ibrahim Omran3; Radwa Mohamed Sabra email 3
1Department of Clinical Oncology and Nuclear Medicine, Ain Shams University
2Department of Clinical Pathology Faculty of Medicine, Ain Shams University
3Maadi Armed Forces Medical Compound
Abstract
Background and Objectives: the use of neoadjuvant chemotherapy (NAC) in breast cancer induces a pCR in only 30–35% of patients. We can’t depend only on clinical and pathological factors to distinguish the patients who have no chance of a pCR or not. Moreover, the NAC scenario is the perfect setting to study possible changes in TIL levels. Tumor-infiltrating lymphocytes (TIL) (CD) 8+ are essential components of tumor-specific cellular adaptive immunity. However, only few studies have addressed the significance of (CD8+) TIL in patients with breast cancer. Patients and Methods: we assessed the stromal and intratumral TIL, CD+8 in pretreatment core biopsy by immuohistochemistry (IHC) in 45 patients with breast cancer received neoadjuvant anthracyclin and docetaxel chemotherapy. CD8 classified into high or low according to the inter quartile range. Tumors with ≥ 50% intratumoral or stromal lymphocytes were designated lymphocyte predominant breast cancer (LPBC). Results: we found statistically significant correlation with high CD8 and DFS and smaller tumor residual (95% CI, 18.6-22.9; P= 0.01) and (p=0.003) respectively. But there was no significant difference regarding pCR or OS between high and low groups. Conclusion: this study confirmed that the CD8 TIL is an important prognostic and predictive factor in breast cancer.
Keywords
breast cancer; CD8; Tumor infiltrating lymphocytes
Statistics
Article View: 189
PDF Download: 341